Earnings summaries and quarterly performance for Progyny.
Executive leadership at Progyny.
Board of directors at Progyny.
Research analysts who have asked questions during Progyny earnings calls.
Jailendra Singh
Truist Securities
6 questions for PGNY
Also covers: ACCD, AGL, AMWL +16 more
Sarah James
Cantor Fitzgerald
6 questions for PGNY
Also covers: ACHC, AMED, ARDT +16 more
Michael Cherny
Leerink Partners
5 questions for PGNY
Also covers: ACCD, ACH, AKBA +23 more
Scott Schoenhaus
KeyBanc Capital Markets
5 questions for PGNY
Also covers: ALIT, CERT, DOCS +9 more
Allen Lutz
Bank of America
3 questions for PGNY
Also covers: ACCD, CAH, COR +15 more
AM
Anne McCormick
JPMorgan Chase & Co.
3 questions for PGNY
Also covers: DOCS, HCAT, HQY +4 more
Brian Tanquilut
Jefferies
3 questions for PGNY
Also covers: ACHC, ADUS, AHCO +31 more
CD
Constantine Davides
Citizens JMP
3 questions for PGNY
Also covers: ADUS, AMN, CCRN +9 more
David Larsen
BTIG
3 questions for PGNY
Also covers: ACCD, AGL, AMWL +20 more
D
Devon
Bank of America
2 questions for PGNY
PW
Peter Warendorf
Barclays
2 questions for PGNY
Also covers: LFST, TALK
Daniel Clark
Leerink Partners
1 question for PGNY
Also covers: CERT, ELAN, IDXX +6 more
GS
Glen Santangelo
Jefferies
1 question for PGNY
Also covers: ALGN, ANIP, BHC +16 more
JS
Jenny Shen
TD Cowen
1 question for PGNY
Also covers: AGL, CCSI, CYRX +8 more
JP
John Penny
Canaccord Genuity
1 question for PGNY
Richard Close
Canaccord Genuity Group
1 question for PGNY
Also covers: ACCD, AHCO, CLOV +15 more
SD
Stephanie Davis
Barclays
1 question for PGNY
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for PGNY.
Progyny Reports Record 2025 Results and Provides 2026 Guidance
PGNY
Earnings
Guidance Update
Share Buyback
- Progyny achieved record financial results in 2025, with revenue of $1.29 billion and adjusted EBITDA of $222 million, both exceeding the midpoint of original guidance.
- The company generated a record $210 million in operating cash flow in 2025, marking a 17% increase over 2024.
- For 2026, Progyny projects revenue between $1.355 billion and $1.405 billion, and adjusted EBITDA between $224 million and $239 million.
- Progyny maintained nearly 100% client retention and saw 30% of its client base expand benefits for 2026, providing over 2.7 million members access to new services.
- In Q4 2025, the company repurchased 3.3 million shares for nearly $84 million, contributing to a total of approximately 6.5 million shares repurchased under its program.
Feb 26, 2026, 9:45 PM
Progyny Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
PGNY
Earnings
Guidance Update
Share Buyback
- Progyny reported record financial results for 2025, with revenue of $1.29 billion and adjusted EBITDA of $222 million, both surpassing original guidance. Operating cash flow also reached a record $210 million, marking a 17% increase over 2024.
- The company achieved a near 100% client retention rate and expanded benefits with 30% of its client base for 2026, which will provide over 2.7 million members access to new services.
- For 2026, Progyny projects revenue between $1.355 billion and $1.405 billion and adjusted EBITDA between $224 million and $239 million. The company anticipates 7.2 million covered lives in 2026, a slight adjustment from earlier estimates.
- In Q4 2025, Progyny repurchased over 3.3 million shares for nearly $84 million under its share repurchase program, with over $40 million still available. Stock-based compensation is expected to decrease by approximately 35% in 2026 compared to 2025.
Feb 26, 2026, 9:45 PM
Progyny Announces Strong Q4 and Full-Year 2025 Results with Positive 2026 Guidance
PGNY
Earnings
Guidance Update
Share Buyback
- Progyny reported Q4 2025 revenue of $318.4 million, a 6.7% increase year-over-year, and full-year 2025 revenue of $1.2887 billion, up 10% from the prior year. Adjusted EBITDA for Q4 2025 increased 8.2% to $51.4 million, with a 16.1% margin, while full-year Adjusted EBITDA grew 12% to $222.1 million, achieving a 17.2% margin.
- The company generated $54.2 million in operating cash flow in Q4 2025 and $210.2 million for the full year 2025. Progyny maintains a strong balance sheet with $310 million in cash, cash equivalents, and marketable securities and no debt as of December 2025.
- During Q4 2025, Progyny repurchased 3,301,596 shares for $83.6 million under its November 2025 share repurchase program. To date, approximately 6.5 million shares have been repurchased for $160 million, with more than $40 million remaining under the existing $200 million authorization.
- For Q1 2026, Progyny expects revenue between $319 million and $332 million and Adjusted EBITDA between $51.0 million and $55.0 million. Full-year 2026 guidance projects revenue in the range of $1.355 billion to $1.405 billion and Adjusted EBITDA between $224.0 million and $239.0 million.
Feb 26, 2026, 9:45 PM
Progyny Reports Strong 2025 Results and Issues 2026 Guidance
PGNY
Earnings
Guidance Update
New Projects/Investments
- Progyny achieved record financial results in 2025, with revenue of $1.29 billion and adjusted EBITDA of $222 million, both exceeding original guidance. Operating cash flow reached a record $210 million, marking a 17% increase over 2024.
- For 2026, the company projects full-year revenue between $1.355 billion and $1.405 billion, and adjusted EBITDA between $224 million and $239 million. This guidance implies revenue growth of 9.3%-13.3% when excluding the impact of a former large client.
- Progyny maintained near 100% client retention for 2026, with 30% of its client base expanding benefits to include new services, providing access to over 2.7 million members.
- The company introduced Progyny Select, a new per member per month (PMPM) model for smaller clients, which is priced with guardrails and a risk premium, and is expected to become more predictable as the pool of lives grows.
Feb 26, 2026, 9:45 PM
Progyny, Inc. Announces Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
PGNY
Earnings
Guidance Update
Share Buyback
- Progyny, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2025, with revenue of $318.4 million in Q4 2025 and $1,288.7 million for the full year, marking increases of 6.7% and 10% respectively.
- The company generated a record $210.2 million in full-year operating cash flow and achieved $222.1 million in Adjusted EBITDA for 2025, a 12% increase over the prior year.
- Progyny returned value to shareholders by repurchasing approximately 6.5 million shares to date under its recent authorization, totaling approximately $160 million.
- For the full year 2026, the company issued financial guidance projecting revenue between $1.355 billion and $1.405 billion and Adjusted EBITDA between $224.0 million and $239.0 million.
- The client base grew to 555 as of December 31, 2025, from 473 in the prior year, with an expectation of approximately 600 clients and 7.2 million covered lives in 2026.
Feb 26, 2026, 9:05 PM
Progyny Highlights Strong Growth and Strategic Expansion
PGNY
Product Launch
M&A
Share Buyback
- Progyny has demonstrated significant financial performance, reporting a 33% revenue CAGR and 51% Adjusted EBITDA CAGR from 2019 through 2025, with $665 million in cumulative operating cash flow from 2019 through September 30, 2025.
- The company showcases effective cost management, with its medical cost trend increasing by 5% from 2022-2025, significantly lower than the 27% U.S. medical cost trend, and achieving ~30% savings through superior clinical outcomes.
- Progyny is expanding its client base, projecting over 600 clients in 2026, and has launched Progyny Select, a pooled risk model for smaller employers, though it is not expected to contribute financially until 2027.
- Strategic growth initiatives include global expansion, marked by the acquisition of Apryl in early 2024, and plans to introduce pregnancy, post-partum, and menopause services in 2026.
- The company maintains strong cash flow conversion, at 80% for 2024 and 9 months of 2025, and prioritizes capital allocation towards share repurchases, business expansion, and disciplined M&A.
Jan 13, 2026, 3:30 PM
Progyny Discusses 2025 Performance, New Products, and 2026 Outlook at J.P. Morgan Healthcare Conference
PGNY
Product Launch
New Projects/Investments
Guidance Update
- Progyny reported a strong 2025 selling season, adding 900,000 lives and achieving near 100% client retention across over 600 clients. The company also highlighted successful diversification, reducing its largest industry concentration from 18% in 2024 to a projected 15% in 2026, and its largest client is expected to represent a mid-single-digit percentage of revenue in 2026.
- The company launched Progyny Select, a new fully insured, pooled risk solution targeting employers with 100+ employees, which expands its addressable market by 50 million additional covered lives. Financial contribution from Select is anticipated starting in 2027.
- Progyny has expanded its service offerings to include pregnancy, postpartum, parenting, leave and benefit navigation, and menopause, with a third of its core book participating in these new services in 2026. The company also expanded its global offering, adding pregnancy, postpartum, and menopause care resources in 2026 following the 2024 acquisition of Apryl.
- Progyny expects fourth-quarter 2025 results to be slightly above its guidance range due to strengthening demand and utilization. The company's capital deployment priorities include expanding offerings, investing in go-to-market, selective M&A, and ongoing share repurchase programs.
Jan 13, 2026, 3:30 PM
Progyny Outlines 2026 Strategy, New Offerings, and Market Diversification
PGNY
Product Launch
New Projects/Investments
Guidance Update
- Progyny introduced Progyny Select, a new fully insured solution for small employers (100+ employees), which expands its addressable market by 50 million additional covered lives and is expected to contribute financially starting in 2027.
- The company reported a successful 2025 selling season, adding 900,000 lives and achieving near 100% client retention, with 30% of clients expanding their benefits.
- Progyny has significantly diversified its client base, reducing its largest industry concentration from 18% in 2024 to 15% in 2026, and projects its largest client to represent only a mid-single-digit percentage of revenue in 2026.
- The company expects fourth-quarter results to be slightly above its guidance range due to strengthening demand and utilization.
- Progyny continues to expand its services, including new offerings for pregnancy, postpartum, parenting, Leave and Benefit Navigation, and menopause, and is expanding its global offering following the 2024 acquisition of Apryl.
Jan 13, 2026, 3:30 PM
Progyny Discusses 2025 Selling Season Success, New Product Launches, and 2026 Outlook
PGNY
Product Launch
New Projects/Investments
Share Buyback
- Progyny reported a successful 2025 selling season, adding an additional 900,000 lives and achieving close to 100% client retention.
- The company has significantly diversified its client base, with the largest industry representing 15% of lives in 2024 (down from 18%) and the largest client projected to be a mid-single-digit client in 2026.
- Progyny launched "Progyny Select," a new solution for small employers (100+ employees) that expands its addressable market by 50 million additional covered lives, with financial contribution expected to begin in 2027.
- The company expects fourth-quarter results to be slightly above its guidance range due to continued and strengthening demand.
- Capital deployment priorities include expanding offerings, investing in go-to-market resources, selective M&A, and returning value to shareholders through share repurchase programs, including a $200 million program announced in November.
Jan 13, 2026, 3:30 PM
Progyny Updates Financial Expectations for Q4 and Full Year 2025
PGNY
Guidance Update
Earnings
Revenue Acceleration/Inflection
- Progyny, Inc. announced it will discuss updated financial expectations for the fourth quarter and full year ending December 31, 2025, at the JP Morgan Healthcare Conference on January 13, 2026.
- The company anticipates its fourth quarter 2025 results for revenue, net income, and Adjusted EBITDA to be slightly above the ranges previously provided in November.
- This positive revision is primarily due to favorable member engagement during the fourth quarter.
Jan 12, 2026, 1:12 PM
Quarterly earnings call transcripts for Progyny.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more